Nuclear Medicine and Molecular Imaging

  • 제43권4호
  • /
  • Pages.253-258
  • /
  • 2009
  • /
  • 1869-3474(pISSN)
  • /
  • 1869-3482(eISSN)
대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

$^{18}$F-Fluoride-PET을 이용한 골격계 영상

$^{18}$F-Fluoride-PET in Skeletal Imaging

  • 전태주 (CHA 의과학대학 분당 차병원 핵의학과)
  • Jeon, Tae-Joo (Departments of Nuclear Medicine, Bundang CHA General Hospital, School of Medicine, CHA University)
  • 발행 : 2009.08.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bone scintigraphy using $^{99m}$Tc-labeled phosphate agents has long been the standard evaluation method for whole skeletal system. However, recent shortage of $^{99m}$Tc supply and advanced positron emission tomography (PET) technology evoked the attention to surrogate radiopharmaceuticals and imaging modalities for bone. Actually, fluorine-18 ($^{18}$F) was the first bone seeking radiotracer before the introduction of $^{99m}$Tc-labeled agents even though its clinical application failed to become pervasive anymore after the rapid spread of Anger type gamma camera systems in early 1970s. However, rapidly developed PET technology made us refocus on the usefulness of $^{18}$F as a PET tracer. Early study comparing $^{18}$F-Na PET scan and planar bone scintigraphy reported that PET has higher sensitivity and specificity in the diagnosis of metastatic bone lesions than planar bone scan. Subsequent reports comparing between PET and both planar and SPECT bone image also revealed better results of PET scan in similar study groups. Rapid clinical application of PET/CT also accumulated considerable amount of experiences in skeletal evaluation and this modality is known to have better diagnostic power than stand alone PET system as well as bone scan. Furthermore $^{18}$F-Na PET/CT revealed better or at least equal results in detection of primary and metastatic bone lesions compared with CT and MRI. Therefore, it is obvious that $^{18}$F-Na PET/CT has potential to become new imaging modality for practical skeletal evaluation so continuous and careful evaluation of this modality and radiopharmaceutical must be required.

키워드

참고문헌

  1. Anger HO. Scintillation camera. Rev Sci Instrtum 1958;29:27-33 https://doi.org/10.1063/1.1715998
  2. Thrall JH. Technetium-99m labeled agents for skeletal imaging. CRC Crit Rev Clin Radiol Nucl Med 1976;8:1-31
  3. Davis MA, Jones AG. Comparison of $^{99m}$Tc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med 1976;6:19-31 https://doi.org/10.1016/S0001-2998(76)80033-5
  4. Bombardieri E, Buscomber J, Lucignani G, Schober O. Advances in Nuclear Oncology Diagnosis and Therapy. London: Informa; 2007. p. 399-400
  5. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with $^{18}$F-fluoride: applying new technology to an old tracer. J Nucl Med 2008;49:68-78
  6. Bombardieri E, Buscomber J, Lucignani G, Schober O. Advances in Nuclear Oncology Diagnosis and Therapy. London: Informa; 2007. p. 408-9
  7. Patton JA, Delbeke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps. J Nucl Med 2000;41:1364-8
  8. Hasegawa BH, Lang TF, Brown EL. Object-specific attenuation correction of SPECT with correlated dual energy x-ray CT. IEEE Trans Nucl Sci 1993;40:1242-52
  9. Chilton HM, Francis MD, Thrall JH. Radiopharmaceuticals for bone and bone marrow imaging. In: Swanson DP, Chilton HM, Thrall JH, eds. Pharmaceuticals in Medical Imaging: Radiopaque contrast media, Radiopharmaceuticals, enhancement agents for magnetic resonance imaging and ultrasound. New York: Macmillan Pub. Co: 1990. p. 537-63
  10. Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of $^{18}$F- fluoride and $^{99m}$Tc-methylene diphosphonate. Semin Nucl Med 2001;31:28-49 https://doi.org/10.1053/snuc.2001.18742
  11. Park-Holohan SJ, Blake GM, Fogelman I. Quantitative studies of bone using $^{18}$F-fluoride and $^{99m}$Tc-methylenc diphosphonate: evaluation of renal and whole blood kinetics. Nucl Med Commun 2001;22:1037-44 https://doi.org/10.1097/00006231-200109000-00014
  12. Anbar M, Ernst N. A distribution study of $^{18}$F-labelled cationic fluorocomplexes in rats. Int J Appl Radial Isot 1962;13:37-51 https://doi.org/10.1016/0020-708X(62)90167-9
  13. Ruth TJ, Wolf AP. Absolute cross sections for the production of fluorine-18 via the $^{18}$O(p,n) $^{18}$F reaction. Radiochimica Acta 1979;26:21-4
  14. Weber DA, Greenberg EJ, Dimich A, Kenny PJ, Rothschild EO, Myers WP, et al. Kinetics of radionuclides used for bone studies. J Nucl Med 1969;10:8-17
  15. Ovadia D, Metser U, Lievshitz G, Yaniv M, Wientroub S, Even-Sapir E. Back pain in adolescents: assessment with integrated $^{18}$F-fluoride positron-emission tomography-computed tomography. J Pediatric Orthop 2007;27:90-3 https://doi.org/10.1097/01.bpo.0000242438.11682.10
  16. Lim R, Fahey FH, Drubach LA, Connolly LP, Treves ST. Early experience with $^{18}$F sodium fluoride bone PET in young patients with back pain. J Pediatric Orthop 2007;27:277-82 https://doi.org/10.1097/BPO.0b013e31803409ba
  17. Forest N, Welch A, Murray AD, Schweiger L, Hutchison J, Ashcroft GP. Femoral head viability after Birmingham resurfacing hip arthroplasty: assessment with use of [$^{18}$F] fluoride positron emission tomography. J Bone Joint Surg Am 2006;88(Suppl 3):84-9 https://doi.org/10.2106/JBJS.F.00877
  18. Piert M, Winter E, Becker GA. Bilger K, Machulla H, Muller-Schauenburg W, et al. Allogenic bone graft viability after hip revision arthroplasty assessed by dynamic [$^{18}$] fluoride ion positron emission tomography. Eur J Nucl Med 1999;26:615-24 https://doi.org/10.1007/s002590050429
  19. Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, et al. Bone metabolic activity measured with positron emission tomography and [$^{18}$] fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab 1993:77:949-55 https://doi.org/10.1210/jc.77.4.949
  20. Hoh CK, Hawkins RA, Dahlbom M. Glaspy JA, Seeger LL, Choi Y, et al. Whole body skeletal imaging with [$^{18}$F] fluoride ion and PET. J Comput Assist Tomorg 1993;17:34-41 https://doi.org/10.1097/00004728-199301000-00005
  21. Tse N, Hoh C, Hwakins R, Phelps M, Glaspy J. Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma. Am J Clin Oncol 1994;17:22-5 https://doi.org/10.1097/00000421-199402000-00006
  22. Schirrmeister H, Guhlmann A. Elsner K, Kotzerke J, Glatting G, Renstschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone sciniraphy versus $^{18}$F PET. J Nucl Med 1999;40:1623-9
  23. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381-9 https://doi.org/10.1200/JCO.1999.17.8.2381
  24. Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and $^{18}$Flabeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42:1800-4
  25. Hetzel M. Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact of patient management. J Bone Miner Res 2003;18:2206-14 https://doi.org/10.1359/jbmr.2003.18.12.2206
  26. Hoegerle S, Juengling F, Otte A. Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [$^{18}$F] fluoride whole body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998;209:253-8 https://doi.org/10.1148/radiology.209.1.9769840
  27. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with $^{18}F$-fluoride PET/CT and comparison between $^{18}F$-fluoride PET and $^{18}F$-fluoride PET/CT. J Nucl Med 2004;45:272-8
  28. Even-Sapir E, Metser U, Mischani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: $^{99m}$Tc-MDP planar bone scintigraphy, single- and multi-field-of view SPECT, $^{18}$F-fluoride PET, and $^{18}$F-fluoride PET/CT. J Nucl Med 2006;47:287-97
  29. ICRP. ICRP Publication 53: Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1987;17:74
  30. ICRP. ICRP Publication 80: Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1999;28:75